Eli Lilly recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over Wegovy in weight management. This promising development was disclosed alongside its participation at the European Congress on Obesity and publication in The New England Journal of Medicine. Despite these headline-grabbing results, Eli Lilly's stock movement remained flat over the last month, aligning with broader market trends, which also showed little change. The company's consistent effort in product innovation, like the positive ACHIEVE-1 Phase 3 results for orforglipron, complements its steady financial performance disclosed in its recent earnings report. We've identified 2 warning signs for Eli Lilly (1 makes us a bit uncomfortable) that you should be aware of.NYSE:LLY Earnings Per Share Growth as at May 2025 This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality. Eli Lilly's recent SURMOUNT-5 trial results underscore its competitive edge in weight management therapies, a key factor in enhancing its market positioning. This innovative progress, while not immediately impacting its share price last month, could fuel future revenue growth, especially with the anticipated release of orforglipron's Phase III data targeting type 2 diabetes and obesity. Over the last five years, Eli Lilly's total return reached a substantial 392.14%, indicating a robust long-term performance. In contrast, over the past year, the company outperformed the US Pharmaceuticals industry, which experienced a 10% decline, though it lagged behind the overall US market's 8% rise. The latest news, combined with Eli Lilly's significant investments in manufacturing and R&D, suggests potential upgrades in revenue and earnings forecasts. Analysts expect earnings to climb to about $31.7 billion by May 2028, reflecting these growth drivers. However, the stock currently trades below the analyst consensus price target of US$981.63, despite its current value of US$775.12. This presents a potential upside for investors, hinting at an opportunity for the share price to rise about 27% to meet analyst expectations. Such projections, though positive, also depend on overcoming challenges like pricing pressures and regulatory risks, which could affect future profitability. Understand Eli Lilly's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Story Continues Companies discussed in this article include NYSE:LLY. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
Eli Lilly (NYSE:LLY) Announces Superior Weight Loss Results for Zepbound Over Wegovy
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...